Spinal Cord Injury Neuroprotection With Glyburide

Drug

General health

Online since 2 November 2021, updated 897 days ago

About this trial

This trial is enrolling individuals with new spinal cord injuries to the cervical (neck) area to test a drug, Glyburide. This drug is approved for use in other diseases, e.g., diabetes type 2. Researchers want to see if the drug is safe and whether it has a protective effect on the nervous system. This trial will also measure effect of this drug on improving neurological recovery. This is an open-label study — all participants will receive the drug and there is no control (comparison) group. Participants will receive the drug (by mouth) within 8 hours of injury, for 3 days. Follow up will occur at days 28, 42, 84, 182 and 365.

Included participants

Gender

All

Age

18 - 80 years

Injury level

C2 - C8

Severity (AIS)?

AIS-A

AIS-B

AIS-C

Time since injury

≤ 8 hours

Injury type

Traumatic

Healthy volunteers

C2-C8

Additionally, participants must

NOT have penetrating injury, e.g. gunshot to knife wound

What’s involved

Type

Drug

Details

Admission at the study site to take the drug within 8 hours of injury. Taking the drug by mouth every 6 hours for 3 days. Starting on admission into the study, study testing and/or data collection will be done until discharge and on Days 14, 28, 42, 84, 182, and 365.

Potential benefits

Main benefits

General health

Additional benefits

Arm/hand function

Sensory function

Standing/walking/mobility

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results